Lantern Pharma Inc.
LTRN
$3.16
-$0.03-0.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.51M | 1.63M | 1.46M | 1.52M | 1.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.77M | 5.90M | 5.18M | 5.41M | 5.73M |
| Operating Income | -4.77M | -5.90M | -5.18M | -5.41M | -5.73M |
| Income Before Tax | -4.54M | -5.88M | -4.51M | -4.96M | -5.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.54M | -5.88M | -4.51M | -4.96M | -5.44M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.54M | -5.88M | -4.51M | -4.96M | -5.44M |
| EBIT | -4.77M | -5.90M | -5.18M | -5.41M | -5.73M |
| EBITDA | -4.77M | -5.89M | -5.18M | -5.40M | -5.73M |
| EPS Basic | -0.42 | -0.54 | -0.42 | -0.46 | -0.51 |
| Normalized Basic EPS | -0.27 | -0.32 | -0.26 | -0.29 | -0.32 |
| EPS Diluted | -0.42 | -0.54 | -0.42 | -0.46 | -0.51 |
| Normalized Diluted EPS | -0.27 | -0.32 | -0.26 | -0.29 | -0.32 |
| Average Basic Shares Outstanding | 10.78M | 10.88M | 10.76M | 10.76M | 10.74M |
| Average Diluted Shares Outstanding | 10.78M | 10.88M | 10.76M | 10.76M | 10.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |